Substance P promoted fracture healing in type 1 diabetic rats by activating the Wnt/β-catenin bone-building pathway, increasing osteogenic markers and reducing bone resorption — effects blocked when the pathway was inhibited by DKK1.
DKK1 reversed all substance P healing effectsWhen the Wnt pathway was blocked by the inhibitor DKK1 at the fracture site, substance P could no longer promote bone formation or reduce bone resorption — proving the healing mechanism depends on Wnt/β-catenin activation
What the researchers found
Substance P (50 mg/ml/kg, intraperitoneal) administered before fracture surgery in type 1 diabetic rats promoted bone healing through multiple measured effects: upregulation of osteogenic markers RUNX2, osterix (OSTX), and osteocalcin (OSTC); optimization of the bone resorption axis with favorable OPG/RANKL/RANK balance; and activation of the Wnt/β-catenin signaling pathway manifested by upregulated β-catenin and LRP5 with downregulated GSK-3β.
Critically, local delivery of the Wnt antagonist DKK1 (via adenovirus) at the fracture site reversed substance P's beneficial effects, confirming that the Wnt/β-catenin pathway is the essential mediator. Radiographic assessment showed reduced gap size in substance P-treated diabetic fractures compared to untreated diabetic fractures.
Why it matters
Diabetic patients experience fracture healing rates 2-3 times slower than non-diabetic patients, with higher rates of non-union and complications. Current treatments are limited to standard fracture care with no approved therapies specifically targeting the diabetic healing deficit. If substance P or NK1R agonists can restore normal bone healing in diabetic patients, it would address a major unmet clinical need affecting millions of people worldwide with diabetes-related fractures.
How the study worked
Type 1 diabetes was induced in rats using streptozotocin (50 mg/kg for 5 consecutive days). Rats were divided into four groups: non-diabetic fractured controls, diabetic fractured (untreated), diabetic fractured + substance P, and diabetic fractured + substance P + DKK1 (Wnt inhibitor delivered via recombinant adenovirus at the fracture site). Bone healing was assessed by radiographic gap measurement. Protein expression of osteogenic markers (RUNX2, OSTX, OSTC), bone resorption markers (OPG, RANKL, RANK), and Wnt pathway markers (β-catenin, LRP5, GSK-3β) was determined by Western blot.
What this study cannot tell us
The study was conducted in rats with chemically induced type 1 diabetes, which may not fully replicate human diabetic bone disease. The substance P dose (50 mg/ml/kg) is very high for in vivo administration, and dose optimization studies were not reported. Only short-term molecular markers were assessed — long-term functional bone strength and complete healing outcomes were not reported. The DKK1 was delivered via adenovirus, which has its own inflammatory effects that could confound results. Type 2 diabetes, which is far more common, was not studied.
How to read the evidence
This is a preclinical animal study with well-designed experimental groups and molecular validation. The inclusion of a mechanistic blocker (DKK1) strengthens the causal evidence for the Wnt pathway mechanism. However, translation from rat models to human clinical outcomes remains uncertain.
When this study was published
Published in 2021, this study reflects recent interest in neuropeptide-mediated bone repair and the Wnt signaling pathway as a therapeutic target in diabetic fracture healing.
The bigger picture
Substance P's role in bone biology has gained increasing attention, complementing its well-known functions in pain signaling and inflammation. This study connects neuropeptide signaling to the Wnt/β-catenin pathway — one of the most important signaling cascades in bone biology and a target of the anti-osteoporosis drug romosozumab (which also works by inhibiting a Wnt antagonist). The finding that a neuropeptide can rescue impaired Wnt signaling in diabetic bone highlights the intimate connection between the nervous system and skeletal repair.
Questions still open
- Could local substance P delivery at fracture sites improve healing outcomes in human diabetic patients?
- Does this mechanism also apply to type 2 diabetic fracture healing, which involves different metabolic pathology?
- Could combining substance P with existing Wnt pathway drugs (like romosozumab) produce synergistic bone healing effects?
Common questions
Why do fractures heal more slowly in people with diabetes?
Could substance P be used to help heal fractures in humans?
Read the original research
Neurokinin-1-tachykinin receptor agonist promotes diabetic fracture healing in rats with type 1 diabetes via modulation of Wnt/β-catenin signalling axis.
Saudi journal of biological sciences, 28(4), 2139-2145
Citation
Wang, Xiaohui; Su, Ning. (2021). Neurokinin-1-tachykinin receptor agonist promotes diabetic fracture healing in rats with type 1 diabetes via modulation of Wnt/β-catenin signalling axis.. Saudi journal of biological sciences, 28(4), 2139-2145. https://doi.org/10.1016/j.sjbs.2021.02.026